Month: October 2025

SHENZHEN, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VISION INTERNATIONAL MANAGEMENT LIMITED entered into a Distribution Agreement (the “Agreement”) with Novartis Pharma Services AG (“Novartis”) for Ranibizumab Injection (“Lucentis®”) and Brolucizumab Injection (“Beovu®”). In accordance with the Agreement, the Group has obtained the exclusive right to import, distribute, sell and promote as specifically agreed upon in the Agreement in the People’s Republic of China (for the purpose of the Agreement, excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) ; Novartis will continue to be responsible for the production and supply of the products. The term of cooperation comes into effect on the effective date of the Agreement and remains valid for a period of five years.Both collaborative products have been approved for marketing in China. Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases. Lucentis® has been approved for the treatment of multiple ocular neovascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), etc. Another product, Beovu®, is a next-generation anti-VEGF drug approved in China in May 2025 for the treatment of DME. Leveraging its innovative advantages of ultra-small molecular weight (only 26 kDa) and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.The Group’s ophthalmology business company, “CMS Vision”, focuses on deploying and developing innovative ophthalmic pharmaceuticals and medical devices with urgent clinical needs on a global scale, striving to become a “leading ophthalmology pharmaceutical company in China”. This collaboration will enhance the overall competitiveness of CMS Vision in the field of ophthalmology. CMS Vision already covers ophthalmic disease areas such as fundus diseases, asthenopia and glaucoma. With the addition of Lucentis® and Beovu®, the portfolio will generate strong synergies with the marketed exclusive drug Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) and the marketed exclusive medical device EyeOP1 Glaucoma Treatment Device in terms of customer base, expert resources, and channel networks. This will further strengthen CMS Vision’s academic brand competitiveness in ophthalmology, provide positive momentum for sustained collaboration and the development of clinically needed innovative ophthalmic products, and offer patients more diverse treatment options. At the same time, CMS Vision’s professional ophthalmology team will integrate marketing channels and academic resources to improve the overall team efficiency. The collaboration is expected to have a positive impact on the Group’s financial results.More Information about LUCENTIS® and Ocular Neovascular DiseasesLucentis® is a recombinant humanized monoclonal antibody Fab fragment targeting VEGF. It targets and inhibits human vascular endothelial growth factor A (VEGF-A), thereby suppressing vascular endothelial cell proliferation, neovascularization, and vascular leakage. As the first anti-VEGF drug approved for ophthalmic use in China[3], Lucentis® has been approved for the treatment of multiple ocular neovascular diseases since its launch in China in 2011, including nAMD, DME, macular edema following RVO, choroidal neovascularization (CNV), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). In 2017, Lucentis® was included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance. It has accumulated mature clinical application experience, providing reliable support for numerous patients with ocular fundus diseases.Ocular neovascular diseases are a group of severe blinding ophthalmic conditions characterized by increased vascular permeability, vascular leakage, and loss of vascular integrity, mainly including nAMD, DR, DME, RVO, CNV, ROP, etc. Anti-VEGF drugs are recommended as first-line therapy for ocular neovascular diseases in multiple authoritative guidelines[3, 4]. According to a Frost & Sullivan report, the number of patients with ocular neovascular diseases in China is projected to increase from 47.8 million in 2019 to 61.2 million in 2030. The Chinese ophthalmic anti-VEGF drug market is expected to grow from RMB 2.4 billion in 2019 to RMB 18.6 billion in 2030. As stated in Anti-VEGF Drugs for Fundus Neovascular Diseases, Lucentis®—the first anti-VEGF drug approved for the treatment of ocular neovascular diseases in China—has demonstrated favorable safety and efficacy in multiple clinical trials. It has been widely used in the treatment of ocular neovascular diseases, and its launch represents a major advancement in clinical ophthalmic treatment[5].More Information about BEOVU® and the DME IndicationBeovu® is a novel VEGF-A-targeted humanized single-chain antibody fragment. It received approval from the National Medical Products Administration of China (NMPA) in May 2025 for the treatment of DME. As the current anti-VEGF drug with the smallest molecular weight (only 26 kDa), Beovu® is administered once every 6 weeks during the loading phase of the DME treatment (compared to once every 4 weeks for other anti-VEGF drugs) and once every two to three months during the maintenance phase. In the global Phase 3 KESTREL and KITE Studies for treatment-naive DME patients, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100. Additionally, patients in the Beovu® 6mg group had less intraretinal fluid (IRF) and/or subretinal fluid (SRF). The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter[6]. Data from the Chinese real-world study (BEST Study) showed that for previously treated and inadequately controlled DME patients, BCVA improved by 6.1 letters from baseline 1 week after the first injection of Beovu®, and by 10 letters after the third injection (Week 12). Beovu® provides a more optimized treatment option for previously treated DME patients[7].DME is a retinal thickening caused by capillary leakage in the macular area, which is the result of the breakdown of the blood retinal barrier and mainly affects central vision.[8]. According to a Frost & Sullivan report, there are approximately 7.89 million DME patients in China in 2025. However, even with the current standard anti-VEGF regimens, approximately 30%-50% of DME patients still exhibit suboptimal fluid control[9-11]. A survey in the 2022 White Paper on the Current Status of Chronic Disease Management for Common Ocular Fundus Diseases in China showed that treatment adherence among Chinese patients is relatively poor, with over 30% of DME patients failing to complete the loading phase treatment. There is an urgent clinical need for more potent, longer-lasting, and more adherence-friendly treatment options to improve the diagnosis and treatment of DME patients. As a next-generation anti-VEGF drug, Beovu® offers a potential solution to this challenge. Leveraging its innovative advantages of ultra-small molecular weight and high concentration, Beovu® significantly improves retinal anatomical structure, helps more DME patients gain visual improvement, and alleviates treatment burden.About NOVARTISNovartis is a globally renowned pharmaceutical company headquartered in Basel, Switzerland. The company focuses on four core therapeutic areas with urgent patient needs—Cardiovascular, Renal and Metabolic Disease, Oncology, Immunology, and Neuroscience—as well as five key technology platforms: Chemotherapy, Biotherapy, xRNA, Radioligand Therapy, and Gene and Cell Therapy.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Product-related information can be found on the Novartis website at:https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications 2. Lim, Jennifer I et al. “Diabetic Retinopathy Preferred Practice Pattern®.” Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China(2023)[J]. Chinese Journal of Ophthalmology,2023,59(5):347-366. 4. Xu Xun, Wang Jianying. Changes in Disease Spectrum Drive the Evolution of Clinical Medications [N]. Health News, 2023-07-05(005).5. Hou Huimin, et al. Anti-VEGF drugs for fundus neovascular diseases[J].International Review of Ophthalmology,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. Honghua Yu, 2025 China Forum on Fundus Diseases & International Retina Symposium, June 4-7, Wuxi, China.8. Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chinese Journal of Ocular Fundus Diseases,2023,39(2):99-124.9. Dai Hong, et al. Advances in the treatment strategies of diabetic macular edema and the problems[J]. Chinese Journal of Ocular Fundus Diseases,2022, 38(1): 6-9.10. Bressler, Neil M et al. “Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.” JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. “Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.” Eye (London, England) vol. 31,11 (2017): 1594-1599.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-DISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics"ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materials they need for robust and efficient drug development."CIL's global manufacturing network, including facilities in North America, Europe, and Asia, enables CIL to provide a diversified and resilient supply chain for pharmaceutical partners. Every ISOAPI-D product is manufactured in ISO 9001-certified facilities, ensuring the highest standards of quality, regulatory compliance, and full traceability throughout the production process.A core component of the ISOAPI-D line is heavy water (D₂O), which is sourced exclusively from approved suppliers. This product is fully traceable and tritium-free, aligning with stringent safety and regulatory requirements of the pharmaceutical industry.The ISOAPI-D range also features advanced intermediates that allow for more streamlined synthetic pathways. By reducing the number of synthesis steps and optimizing production efficiency, these intermediates can help lower manufacturing costs and accelerate the time to market for new therapeutics.Since 1981, CIL has been a trusted supplier of premium deuterated materials to leading pharmaceutical and biotechnology companies worldwide. This longstanding commitment to quality and reliability continues with the launch of ISOAPI-D, offering customers a secure, high-quality supply of essential reagents and reducing operational risk in their development pipelines."ISOAPI-D represents the next step in our ongoing mission to support pharmaceutical innovation," said Tasha Agreste, Business Development Manager Deuterated Reagent Applications, at CIL. "Our expanded manufacturing capabilities, rigorous quality standards, and decades of experience position CIL as a reliable partner for the industry's evolving needs."Visit CIL at CPhI Frankfurt, Stand #2.0G2, October 28-30, to discover ISOAPI-D, the future of deuterated chemistry for pharmaceuticals.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds.Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TEWKSBURY, MA AND HYDERABAD, INDIA, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) - Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continuity. The forthcoming entity, Cambridge Isotope Laboratories, Pvt. Ltd., is expected to be officially established in Q4 2025, subject to customary diligence and closing considerations. Operations for the newly formed entity will be initiated at existing CCS facilities, with a net new facility slated for groundbreaking in 2026. The new facility will be located in India's Genome Valley, a burgeoning 2,000-acre life sciences cluster located in suburban Hyderabad.Cliff Caldwell, CEO at CIL noted, "We are excited to partner with CCS to combine our chemistry expertise and pursue scale-up technologies to further support pharmaceutical and industrial applications. This initiative reflects our commitment to supporting global research and development efforts in scientific fields as well as supporting the growing commercial needs for deuterium labeled and specialty chemical products in the pharmaceutical and electronics industries."Vishal Rajput, CEO of CCS said, "The collaboration and newly formed entity will leverage CCS's strong infrastructure and deep technical capabilities in India, while integrating CIL's world-class standards in isotope chemistry, quality systems, global logistics and go-to market capabilities." Mr. Rajput will lead the newly formed entity as general manager of Cambridge Isotope Laboratories, Pvt. Ltd. The legacy CCS business will remain intact, with the collective intent to expand access to high quality, isotopically labeled and unlabeled compounds for customers worldwide, with an emphasis on downstream synthetic compounds and a commitment to industry-specific product quality requirements.All CIL, Eurisotop and CCS branded and manufactured materials remain available to Indian and worldwide customers through existing channels. Further details regarding the launch and operational scope of Cambridge Isotope Labs Pvt. Ltd. will be shared in the coming months.About Cambridge Isotope Laboratories, Inc.CIL, a subsidiary of Otsuka Pharmaceutical in Japan, is the largest manufacturer and global supplier in the world of stable isotopes and stable isotope‑labeled compounds. Trusted by industrial and academic collaborators since 1980, CIL's products are used in research, diagnostics, environmental, pharmaceutical, medical diagnostic, OLED, and industrial applications. CIL's operations include two facilities in the Boston, MA, area; a large isotope‑enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany (specializing in radioisotopic‑labeled compounds for cancer diagnosis and treatment); and Eurisotop in Saclay, France.About Chemtatva Chiral Solutions, Pvt. Ltd.CCS is a Hyderabad-based company founded in 2021, specializing in chiral chemistry, process development, and custom synthesis for pharmaceutical and chemical industries. CCS is a trusted global partner in life sciences, delivering innovative chemistry solutions that solve complex challenges and accelerate scientific progress.Contact InformationCrissy Kriskocrissyk@isotope.com1.978.269.1930SOURCE: Cambridge Isotope Laboratories, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2025年10月27日 - (亚太商訊) - 康哲药业控股有限公司（"康哲药业"）欣然宣布，于2025年10月27日，康哲药业通过子公司CMS VISION INTERNATIONAL MANAGEMENT LIMITED与Novartis Pharma Services AG （"诺华"）就雷珠单抗注射液（"诺适得(R)"）、布西珠单抗注射液（"倍优适(R)"）签订经销协议（"协议"）。根据协议，康哲药业获得产品在中华人民共和国（为协议之目的，不含香港特别行政区、澳门特别行政区、台湾）的协议所约定之独家进口、经销、销售、推广权利；诺华继续负责生产、供应产品。合作期限为协议约定的生效日起五年。两款合作产品均已在中国获批上市，其中诺适得(R)是中国首个获批用于眼科的抗血管内皮生长因子（VEGF）药物，具备成熟的临床应用经验，为众多眼底疾病患者提供了可靠保障；诺适得(R)已被批准用于治疗湿性年龄相关性黄斑变性（nAMD）、糖尿病性黄斑水肿(DME)、视网膜静脉阻塞(RVO)继发的黄斑水肿等多项眼底新生血管性疾病。另一款产品倍优适(R)为新一代抗VEGF药物，2025年5月中国获批用于DME，其凭借独特的超小分子（仅26kDa）、高浓度创新优势，显著改善视网膜解剖学结构，助力更多DME患者获得视力改善，减轻治疗负担。康哲药业眼科业务公司"康哲维盛"专注于在全球范围内布局、开发临床急需的眼科药械创新产品，致力于打造"中国眼科医药龙头"，此次合作将提升康哲维盛在眼科领域的整体竞争力。康哲维盛已覆盖眼底疾病、视疲劳、青光眼等眼科疾病领域，诺适得(R)及倍优适(R)加入后，将与在售独家药施图伦滴眼液（七叶洋地黄双苷滴眼液）、在售独家医疗器械EyeOP1青光眼治疗仪在客户、专家资源、渠道网络上产生高度协同，提升康哲维盛在眼科领域的学术品牌竞争力，为持续合作、开发临床急需的眼科创新产品带来正向推动作用，为眼科疾病患者提供更多元化的治疗选择。同时康哲维盛专业的眼科团队将整合市场渠道与学术资源，提升团队整体效能，并预期对康哲药业业绩产生积极正面影响。关于诺适得(R)及眼底新生血管性疾病的更多信息诺适得(R)是重组抗VEGF人源化单克隆抗体Fab片段，靶向抑制人血管内皮生长因子A（VEGF-A），以抑制血管内皮细胞增殖、新生血管生成和血管渗漏。诺适得(R)作为中国首个获批用于眼科的抗VEGF药物[3]，自2011年在中国上市以来，已被批准用于治疗多项眼底新生血管性疾病，包括nAMD、DME、RVO继发的黄斑水肿、脉络膜新生血管(CNV)、糖尿病视网膜病变（DR）、早产儿视网膜病变(ROP)。诺适得(R)已于2017年被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》，具备成熟的临床应用经验，为众多眼底疾病患者提供了可靠保障。眼底新生血管性疾病是一类以血管通透性增加、血管渗漏以及血管完整性的缺失为特征的严重致盲性眼病，主要包括nAMD、DR、DME、RVO、CNV、ROP等。抗VEGF药物是多个权威指南推荐治疗眼底新生血管性疾病的一线疗法[3, 4]。根据弗若斯特沙利文报告，中国眼底新生血管性疾病患者预计将从2019年的47.8百万人增至2030年的61.2百万人。中国抗VEGF眼科药物市场预期将从2019年的24亿元增长至2030年的186亿元。根据《抗VEGF药物治疗眼底新生血管性疾病》，诺适得(R)作为中国首个获批用于治疗眼底新生血管性疾病的抗VEGF药物，在多项临床试验中均显示出良好的安全性和有效性，已被广泛应用于治疗眼底新生血管性疾病，它的问世代表了眼科临床治疗的一个重大进步[5]。关于倍优适(R)及DME适应症的更多信息倍优适(R)是一种靶向VEGF-A的新型人源化单链抗体片段，已于2025年5月获得中国国家药品监督管理局批准用于DME。作为目前分子量最小的抗VEGF药物（仅26kDa），倍优适(R)治疗DME负荷期每6周给药一次（其他抗VEGF药物负荷期每4周给药1次），维持期每2至3个月给药一次。倍优适(R)针对初治DME患者的全球3期KESTREL和KITE研究均达到主要疗效终点且视力获益持续至100周。倍优适(R)6mg组患者IRF（视网膜内积液）和/或SRF（视网膜下积液）更少。倍优适(R)首年中位注射次数（7次）少于阿柏西普（9次），同时总体安全性与后者相当[6]。中国真实世界研究BEST研究显示，经治不达标的DME患者经倍优适(R)首针治疗1周后BCVA即较基线提升6.1字母，注射第3针（12周）提升10字母，倍优适(R)为经治DME提供更优化的治疗选择[7]。DME是由于黄斑区毛细血管渗漏所致的视网膜增厚，是血视网膜屏障破坏的结果，主要影响中心视力[8]。据弗若斯特沙利文报告，2025年中国约有7.89百万例DME患者。但即使按目前规范的抗VEGF药物治疗方案，仍有约30%-50%DME患者积液控制不佳[9-11]。《2022中国常见眼底病慢病管理现状白皮书》调研显示，我国患者治疗依从性较差，30%以上DME患者未能完成负荷期治疗。临床亟需更强效、更持久、依从性更高的治疗药物以改善DME患者的诊疗现状。新一代抗VEGF药物倍优适(R)为解决这一难题提供了潜在方法，其凭借独特的超小分子、高浓度创新优势，显著改善视网膜解剖学结构，助力更多DME患者获得视力改善，减轻治疗负担。关于诺华诺华是一家全球知名的医药企业，总部位于瑞士巴塞尔。诺华聚焦患者需求紧迫的四大核心治疗领域（心血管、肾脏及代谢，肿瘤，免疫，神经科学）以及五大关键技术平台（化学疗法、生物疗法、xRNA疗法、放射配体疗法、基因和细胞疗法）。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. 产品相关信息可在诺华官网查询，网址：https://www.novartis.com.cn/news/big-news-noxtex-welcomes-the-approval-of-dual-indications2. Lim, Jennifer I et al. "Diabetic Retinopathy Preferred Practice Pattern(R)." Ophthalmology vol. 132,4 (2025): P75-P162. doi:10.1016/j.ophtha.2024.12.0203. 中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病学组.中国年龄相关性黄斑变性临床诊疗指南(2023年)[J].中华眼科杂志,2023,59(5):347-366.4. 许迅,王建影.疾病谱变化驱动临床药物更迭[N].健康报,2023-07-05(005).5. 侯慧敏,常雪柯,靳雨佳,等.抗VEGF药物治疗眼底新生血管性疾病[J].国际眼科纵览,2024,48(6):464-470.6. Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diaßbetic Macular Edema. Am J Ophthalmol. 2024;260:70-83.7. 余洪华，2025中国眼底病论坛暨国际视网膜研讨会，6月4日-7日，中国无锡8. 中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)[J]. 中华眼底病杂志,2023,39(2):99-124.9. 戴虹, 卢颖毅. 糖尿病黄斑水肿治疗策略的变化与面临的问题[J].中华眼底病杂志, 2022, 38(1): 6-9.10. Bressler, Neil M et al. "Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial." JAMA ophthalmology vol. 136,3 (2018): 257-269.11. Chatziralli, I et al. "Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data." Eye (London, England) vol. 31,11 (2017): 1594-1599.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – CTF Life today announced the signing of a Memorandum of Understanding with Gleneagles Hospital Hong Kong (“Gleneagles”), CUHK Medical Centre (“CUHKMC”), and Hong Kong Baptist Hospital (“HKBH”) to establish strategic partnerships. In a pioneering move, CTF Life has also become the first insurance company to collaborate with Gleneagles MediCentre in Admiralty to launch an exclusive programme to provide customers with health management solutions. At the same time, the PrimeChamp Doctor Network has been enhanced with the official inclusion of the three hospitals and their affiliated medical centres. This expanded medical network now spans across Hong Kong, offering customers priority referrals, appointment scheduling and direct billing services.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said, “We are pleased to forge long-term business partnerships with three leading and distinguished hospitals. Harnessing the strengths of the Chow Tai Fook Group ecosystem, we are committed to providing our customers with more flexible and superior medical service solutions, serving as their Life Planner. This collaboration not only further solidifies our medical network across Hong Kong, but also elevates the overall service experience at CTF Life, empowering customers with greater autonomy, convenience and comprehensive medical service experiences at every stage of their life journey. We firmly believe that medical protection should go beyond claims, it should accompany our customers across every stage from prevention and diagnosis to treatment and recovery, truly bringing to life our vision of creating value beyond healthcare.”Territory-wide Medical Network Coverage Across Hong KongThe three hospitals will respectively serve as CTF Life’s designated medical network partners on Hong Kong Island, Kowloon, and the New Territories. Their doctors and mental health therapists will also join the PrimeChamp Doctor Network, providing customers with convenient, high-quality, and comprehensive medical services.Hong Kong Island: Gleneagles Hospital Hong KongGleneagles serves as the appointed medical network partner for Hong Kong Island. CTF Life has also become the first insurance company to collaborate with the newly opened Gleneagles MediCentre in Admiralty, further expanding its service scope through exclusive programmes. These programmes include gastroscopy, colonoscopy and wart removal services, providing customers with prevention-oriented health management solutions.New Territories: CUHK Medical CentreCUHKMC will serve as the selected medical network partner for the New Territories. Backed by a top-tier medical team comprising professors from the CUHK Faculty of Medicine and specialists, coupled with advanced medical facilities and strong research capabilities, CUHKMC provides customers with premium, multi-specialty medical services. Dedicated to translating cutting-edge international medical research into clinical practice, CUHKMC delivers a world-class diagnostic and treatment experience that benefits both customers and the wider community.Kowloon: Hong Kong Baptist HospitalHKBH will serve as the designated medical network partner for Kowloon. Operating under a “One Hospital, Multiple Service Sites” synergy model, the hospital enables patients to conveniently access medical services close to their preferred location. Among these sites, the HKBH East Kowloon Medical Centre (EKMC), located in the Kwun Tong Business District (Ngau Tau Kok), provides pre-approved direct billing services for cataract surgery and oncology treatments. Additionally, mental health team offers professional guidance to help individuals better understand and manage their psychological well-being. Together, these services embrace the Hospital mission: “In the Service of Man, for the Glory of God.”Customer-Exclusive Medical Services Reflects a People-Centric ApproachThrough this collaboration, the three hospitals will offer the following services for CTF Life customers:- Priority referral and appointment scheduling, significantly reducing waiting time.- Direct billing services, allowing customers to receive treatment without upfront payment, easing financial pressure.- One-stop cancer treatment services, covering diagnosis, treatment, and post-surgery rehabilitation, providing comprehensive support throughout the care journey.- Access to premium medical services and coordination, arranging professor-level doctors and advanced medical facilities to ensure customers receive the highest quality of medical care.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (middle); Ellick Tsui, Executive Director, Deputy Chief Executive Officer and Chief Financial Officer of CTF Life (second from right); Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong (second from left); Dr Chung Kin Lai, Chief Executive Officer of CUHK Medical Centre (first from right); and Dr Leung Chi Bon, Chief Executive Officer of Hong Kong Baptist Hospital (first from left), announce the establishment of strategic partnerships at the kick-off ceremony.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.Media enquiriesCTF LifeCorporate Communications DepartmentVecinia Lau+852 2591 8297vecinia.lau@ctflife.com.hk Chow Tai Fook Life Insurance Company Limited (Incorporated in Bermuda with limited liability) Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月27日 - (亚太商訊) - 周大福人寿今日宣布，与港怡医院、香港中文大学医院（「中大医院」）及香港浸信会医院（「浸会医院」）签署合作备忘录，建立策略性合作伙伴关系。周大福人寿更成为首间保险公司与港怡医院其位于金钟之日间医疗中心合作推出专属计划，为客户提供健康管理方案。同时，「尚逸医生网络」全面升级，三家医院及其附属医疗中心正式加入，组成更强大的医疗网络，覆盖全港，为客户提供优先转介、预约及直接结算服务。周大福人寿执行董事兼行政总裁叶文杰表示：「我们非常高兴与三家具领导地位的卓越医院建立长远合作关系，透过周大福集团生态圈的优势，为客户提供更灵活和优质的医疗服务方案，成为他们的人生规划师 。是次合作不仅进一步巩固我们全港的医疗网络，同时亦进一步提升了周大福人寿的服务质量，让客户在不同人生阶段，能享有更自主、便捷和全面的医疗服务体验。我们坚信，医疗保障不应止于理赔，应延伸至预防、诊断、治疗及康复的每一个阶段，真正实践开创健康新价值。」三区医疗网络布局 实现全港覆盖三家医院将分别成为周大福人寿于港岛、九龙、新界区的指定医疗网络，医院医生及心理健康治疗师亦会加入「尚逸医生网络」，为客户提供便捷、优质和全面的医疗服务。港岛区：港怡医院港怡医院是港岛区的指定医疗网络。为进一步扩展服务范畴，周大福人寿更成为首间保险公司与港怡医院位于金钟、新开幕之港怡日间医疗中心合作，推出涵盖「肠胃镜检查」及「疣切除」的专属计划，为客户提供以预防为本的健康管理方案。新界区：中大医院中大医院将成为新界区的指定医疗网络。中大医院拥有由中大医学院教授及专科医生组成的顶尖医护团队，再配合其先进的医疗设施与科研实力，为客户提供涵盖多个专科的高端医疗服务。医院致力将国际前沿医研成果转化为临床服务，为客户带来世界级的诊疗体验，惠及社会大众。九龙区：浸会医院浸会医院将成为九龙区的指定医疗网络。浸会医院采用「一院多点」的营运模式，让客户能够就近获得所需医疗服务。其中，位于观塘商贸区（牛头角）的浸信会东九龙医疗中心（EKMC）提供白内障手术及肿瘤科预先批核直付服务; 其心理健康治疗师团队亦会为客户提供身心灵全方位的照顾，秉持着「全人医治．荣神益人」的精神。客户专属医疗服务 体现以人为本精神透过是次合作，三家医院将为周大福人寿客户提供以下服务：- 优先转介及预约安排，大幅缩短轮候时间- 直接结算服务，客户无需预先垫支医疗费用，减轻财务压力- 一站式癌症治疗服务，涵盖诊断、治疗、及术后康复，全程支援照顾- 高端医疗对接，为尊贵客户安排教授级医生及先进医疗设施，确保最优质的医疗照顾周大福人寿执行董事兼行政总裁叶文杰 (中) 、周大福人寿执行董事兼副行政总裁暨首席财务官徐志坚(右二) 、IHH医疗 (北亚洲) 区域首席执行官兼港怡医院执行总裁曾庆亷医生(左二)、香港中文大学医院行政总裁钟健礼医生(右一) 以及香港浸信会医院行政总监梁志邦医生(左一) 出席启动礼，宣布周大福人寿与三大医院建立策略性合作伙伴关系。关于周大福人寿 周大福人寿保险有限公司（「周大福人寿」）扎根香港40年，为周大福创建有限公司（「周大福创建」）（香港股份代号：659）的全资附属公司，也是香港最具规模的寿险公司之一。作为周大福企业成员，周大福人寿紧扣郑氏家族（「周大福集团」或「集团」）生态圈的雄厚资源，致力为客户及其挚爱于「生活、成长、健康、传承」的人生旅程中，提供个人化的匠心规划、终身保障及优质体验。凭借集团财务实力及环球投资布局，周大福人寿矢志成为亚太区领先的保险公司，持续开创保险新价值。传媒联络周大福人寿企业传讯部柳丽凤+852 2591 8297vecinia.lau@ctflife.com.hk周大福人寿保险有限公司（于百慕达注册成立之有限公司） Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- The 27th Hong Kong International Lighting Fair (Autumn Edition) opened today and will run for four days, and the 10th Hong Kong International Outdoor and Tech Light Expo will open tomorrow. The twin lighting fairs bring together some 3,000 exhibitors from 20 countries and regions.- The returning Innovative Lighting Design Forum held today features case studies and global market insights.- Renowned lighting designer Tino Kwan will host a masterclass tomorrow (28 October) at HKCEC titled “The Language of Light: From Artistic Design to Everyday Experience.”- Several exhibitors set up immersive experience zones, to enable visitors to explore product trends in human-centric lighting, artificial intelligence, and the silver market.HONG KONG, Oct 27, 2025 - (ACN Newswire via SeaPRwire.com) – The 27th Hong Kong International Lighting Fair (Autumn Edition), organised by the Hong Kong Trade Development Council (HKTDC), opened today and will run for four days until 30 October at the Hong Kong Convention and Exhibition Centre, while the 10th Hong Kong International Outdoor and Tech Light Expo will take place from 28 to 31 October at AsiaWorld-Expo.Deputy Executive Director of the HKTDC Jenny Koo said: "The development of innovative lighting products is thriving, with significant growth potential. Under the theme “Illuminated Designs for a Smarter Future”, the twin lighting fairs showcase innovative products and smart lighting solutions from some 3,000 exhibitors across 20 countries and regions. The fairs are highly international, in addition to exhibitors from Hong Kong, the Chinese Mainland and Taiwan, we also welcome exhibitors from Denmark, Finland, Germany, the Netherlands, the United Kingdom and the United States.”Centred on innovation and smart design, the Hall of Connected Lighting, which was upgraded last year, returns as the event’s focal point. The hall features some 70 leading brands, with an increase in the number of brands, countries and regions represented. In addition to showcasing a wide range of innovative smart lighting products and solutions, the hall also features several specially designed experience zones, showcasing meticulously designed scenarios, cutting-edge applications, and technologies. In the experience zone, visitors will be immersed in a multi-dimensional light installation that fuses art and technology, and experience a hands-on encounter with AI integrated applications in health and wellness, as well as innovative solutions for the silver market. The Hall of Connected Lighting features renowned brands such as Casambi from Finland, Moorgen from Germany, Signify from the Netherlands, and Koizumi from Japan, showcasing award-winning designs, designer collections, and lamps and lighting solutions used in iconic projects around the world. Major industry alliances playing key roles in the fields of smart lighting and the Internet of Things are gathered at the fair, including the DALI Alliance and SILA-EMN Alliance, as well as new participants this year such as the Connectivity Standards Alliance and the Zhaga Consortium, collectively presenting the full spectrum of the smart lighting ecosystem. They bring together member enterprises from around the world, including Elite Intelligence, Broadlink and Inventronics from the Chinese Mainland, LEDiL from Finland, France’s Nicolaudie, and Germany’s CUPOWER to showcase the smart lighting ecosystem.Another highlight is the Hall of Aurora, which brings together some 540 renowned brands offering high-quality lighting products. They include Prosperity Group and General Lighting from Hong Kong, LEEDARSON, Tospo and Je Woo from the Chinese Mainland, Lival from Finland and Megaman from Germany. Other featured zones include Commercial Lighting, LED Essentials, LED Lighting, Residential Lighting and Testing, Certification & Inspection, providing buyers with one-stop sourcing opportunities.The Hong Kong International Outdoor and Tech Light Expo showcases a diverse range of outdoor commercial and industrial lighting solutions, enabling the development of smart cities. The Smart Pole and Solution Zone, introduced last year, will return to showcase innovative solutions that aid in enhancing the quality of life and energy efficiency optimisation. E-Lite Semiconductor Inc. showcases its smart light poles, equipped with energy-efficient LED lighting and Environmental Sensing technology. These poles monitor air quality, temperature, humidity, and noise levels, and assist with real-time traffic monitoring when integrated with traffic cameras and sensors. Furthermore, Shenzhen Zhongchuang Lighting Technology presents its patented modular square stadium lights in the Technical & Professional Lighting zone. Engineered for functionality, the product allows for individual module replacement in the event of damage – greatly simplifying installation and maintenance while reducing operational costs. The Horticultural Lighting zone showcases advanced horticultural lighting technologies and multifunctional lamps suitable for outdoor parks and home gardens. The Outdoor and Public Lighting zone continues to showcase lamps designed for outdoor public spaces and advertising.Twin fairs focus on multiple lighting trendsImmersive smart lighting experience and design master series Smart homes are becoming increasingly popular. According to Statista, smart lighting is projected to become a massive $44 billion market by 2030, allowing users to adjust brightness, colour and temperature as needed. Exhibitors at this year's Autumn Lighting Fair have also thoughtfully designed various settings to offer buyers hands-on experiences. For example, Casambi has created the Artisan Café, a boutique coffee space illuminated in collaboration with ERCO, a globally acclaimed architectural and commercial lighting brand. Combining digital lighting systems with on-site ambiance, the café offers attendees a unique and immersive experience to connect and exchange ideas while enjoying their coffee. The lighting is configured to simulate natural light at different times of the day, featuring four distinct scenario demonstrations. TUYA Smart has constructed scenes such as living room and a bedroom to demonstrate how lighting and AI technologies can be integrated into smart lighting solutions. Moorgen also presents several cross-over collections from global design masters, including smart lamps designed in collaboration with two receivers of the DFA World’s Outstanding Chinese Designer Award, Chi-wing Lo and Tino Kwan; acclaimed Hong Kong architect, interior and product designer Steve Leung; Spanish designer Jorge Herrera; and internationally renowned design studio Yabu Pushelberg. Among the innovations on show, the Flower of Paris Motorised Track Light makes its global debut at the Autumn Lighting Fair and features a design collaboration with Ma Yansong – the first architect from the Chinese Mainland to win the right to design an international landmark building. As the result of two years’ development, the track light features a 355-degree rotating head and adjustable beam angles of 10, 15 and 25 degrees, flexibly illuminating every detail. Equipped with an intelligent control system, the track light can be operated remotely with effortless scene switches. Architectural lighting fixtures designed by Tino Kwan also makes a Hong Kong debut.Lighting and health are interdependent "Human-centric lighting" will continue to be a key focus in 2025. From lighting solutions that align with circadian rhythms to antibacterial UV-C technology, lighting is becoming a tool for enhancing health. Signify unveils its VitaUp Vitamin D3 Modules by Philips at the fair, offering a safe, controlled source of low-intensity UVB exposure to naturally support healthy vitamin D levels. Designed for long-term and low-intensity use, five-days of exposure delivers the equivalent UVB dose of a 15-minute midday walk two to three times per week in spring or summer. Another highlight is that Jiangsu Insona Communication Technology Co. also brings a smart lighting system that uses a circadian algorithm synchronised with local sunrise and sunset times without requiring network connectivity, thereby supporting the body’s natural biological rhythm. Foshan Electrical and Lighting Co. also sets up an experience zone to launch its Eye-care Ceiling Light, specially designed to meet the needs of the silver market. Tailored for elderly people, the light improves visual clarity by 15%, supports circadian rhythm and boosts lighting efficiency by 12%, reducing eye fatigue.Award-winning designs and global landmark lighting showcased at the twin fairs According to a lighting industry survey conducted by the HKTDC in April, 37% of respondents believe LED lighting has the greatest growth potential. A wide array of LED-innovations are on display, including the Filmbase flying screen developed by Filmbase Tech, a national-level high-tech and Specialised, Refined, Distinctive and Innovative enterprise. This ground-breaking product has set a new Guinness World Record as the world’s largest LED mesh mid-air suspended screen. Hong Kong’s GRE Alpha brings LED drivers and light strings that were used in the lighting show and horticultural system at Gardens by the Bay in Singapore. General Lighting Innovation showcases its Neon Strip which is renowned for its exceptional flexibility, impact resistance and all-weather durability. The latest models allow custom cutting and instant connection on site, enabling versatile installation to suit various spatial designs and creative lighting applications. At the Hong Kong International Outdoor and Tech Light Expo, AGC Lighting Co showcases several outdoor lighting fixtures that have won the German IF Design Award and the Red Dot Design Concept Award. Among them, the UFO High Bay Light features a unique design, enhanced by precision optics and high-efficiency power components. Its integrated system allows for both power and correlated colour temperature (CCT) adjustments in the one fixture.Experts discuss market trendsThe Innovative Lighting Design Forum held today (27 October) at the HKCEC explored two key themes: “City Design.Design City: Lighting Design Bound Up with Daily Life” and “RCEP Opportunities Shining Through Cultural Lighting Design”. Speakers included representatives from celebrated international and local companies, as well as architects and lighting designers, who shared top design cases from various regions and analysed market trends. Tomorrow (28 October), the Connected Lighting Forum will delve into smart living ecosystems and sustainable lighting development. It will also feature the launch ceremony for “Edge Mixed Networking (EMN) Technical Requirements for Smart Buildings”. On the same afternoon, renowned lighting designer Tino Kwan will host a masterclass titled “The Language of Light: From Artistic Design to Everyday Experience” and share design principles for enhancing daily life through light and the impact of light on mood, functionality and spatial characteristics. Additionally, a seminar titled “Illuminating the Cycle: Outdoor Lighting Designs for a Sustainable Future” will be held tomorrow (28 October) at AsiaWorld-Expo, focusing on how outdoor lighting can integrate sustainability concepts.Running concurrently from 28 to 31 October, the Outdoor and Tech Light Expo and Eco Expo Asia at AsiaWorld-Expo, alongside the Autumn Lighting Fair at the Hong Kong Convention and Exhibition Centre (HKCEC), present a dynamic platform for cross-sector business opportunities. Free shuttle bus services will be provided between the HKCEC and AsiaWorld-Expo from 28 to 30 October.Under the EXHIBITION+ hybrid model, exhibitors and buyers can meet online through the Click2Match business matching platform in addition to attending the physical fair. The online fairs run from 20 October to 7 November, facilitating business expansion both online and offline. 27th HKTDC Hong Kong International Lighting Fair (Autumn Edition)10th HKTDC Hong Kong International Outdoor and Tech Light ExpoDate27-30 Oct 2025 (Monday to Thursday)28-31 Oct 2025 (Tuesday to Friday)Opening hours27-29 Oct 2025: 9:30am-7pm30 Oct 2025: 9:30am-4pm28 Oct 2025: 10:30am-6pm29-30 Oct 2025: 10am-6pm31 Oct 2025: 10am-5pmVenueHong Kong Convention and Exhibition CentreAsiaWorld-ExpoPress Registration CounterHall 1C Concourse, HKCEC, or at the HKTDC Media Centre (G/F, HKCEC, 1 Expo Drive, Wan Chai)AsiaWorld-Expo East LobbyMedia CentreHKTDC Media CentreRoom 108, Hall 8 Side Entrance, AsiaWorld-ExpoFair websitehklightingfairae.hktdc.com/tchkotlexpo.hktdc.comPhoto download: http://bit.ly/43F182CThe 27th HKTDC Hong Kong International Lighting Fair (Autumn Edition) opens today, showcasing a wide variety of smart lighting products and solutions.The Hall of Connected Lighting returns, showcasing designs and smart technologies from prominent companies and brands.Under the theme ‘Illuminated Designs for a Smarter Future’, exhibitors at the twin lighting fairs present multiple experiential zones featuring meticulously designed lighting scenes, cutting-edge applications, and technologies, allowing visitors to immerse themselves in a multi-dimensional light and shadow experience at the intersection of art and technology.The Hall of Aurora brings together some 540 notable brands offering high-quality lighting products and technologies.The Innovative Lighting Design Forum took place today and explored two key themes: “City Design.Design City: Lighting Design Bound Up with Daily Life” and “RCEP Opportunities Shining Through Cultural Lighting Design”. Representatives from celebrated international and local companies, as well as architects and lighting designers, shared design works from various regions and analysed market trends.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com